Dysregulation of protein phosphatase 2A in parkinson disease and dementia with lewy bodies
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
Objective: Protein phosphatase 2A (PP 2A) is a heterotrimeric holoenzyme composed of a catalytic C subunit, a structural A subunit, and one of several regulatory B subunits that confer substrate specificity. The assembly and activity of PP 2A are regulated by reversible methylation of the C subunit. α‐Synuclein, which aggregates in Parkinson disease (PD) and dementia with Lewy bodies (DLB), is phosphorylated at Ser 129, and PP 2A containing a B55 α subunit is a major phospho‐Ser 129 phosphatase. The objective of this study was to investigate PP 2A in α‐synucleinopathies. Methods: We compared the state of PP 2A methylation, as well as the expression of its methylating enzyme, leucine carboxyl methyltransferase (LCMT‐1), and demethylating enzyme, protein phosphatase methylesterase (PME‐1), in postmortem brains from PD and DLB cases as well as age‐matched Controls. Immunohistochemical studies and quantitative image analysis were employed. Results: LCMT‐1 was significantly reduced in the substantia nigra (SN) and frontal cortex in both PD and DLB. PME‐1, on the other hand, was elevated in the PD SN. In concert with these changes, the ratio of methylated PP 2A to demethylated PP 2A was markedly decreased in PD and DLB brains in both SN and frontal cortex. No changes in total PP 2A or total B55 α subunit were detected. Interpretation: These findings support the hypothesis that PP 2A dysregulation in α‐synucleinopathies may contribute to the accumulation of hyperphosphorylated α‐synuclein and to the disease process, raising the possibility that pharmacological means to enhance PP 2A phosphatase activity may be a useful disease‐modifying therapeutic approach.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
Multicenter Analysis of Glucocerebrosidase Mutations in Parkinson's Disease
Sidransky, E., Nalls, M. A., Aasly, J. O., Aharon-Peretz, J., Annesi, G., Barbosa, E. R., Bar-Shira, A., Berg, D., Bras, J., Brice, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0901281 · Cited by 2,135
The Role of Oxidative Stress in Parkinson's Disease
Dias, V., Junn, E., & Mouradian, M. M. (2013) · Journal of Parkinson’s Disease · doi:10.3233/jpd-130230 · Cited by 1,845
Self-citationSerine/threonine phosphatases: mechanism through structure
Shi, Y. (2009) · Cell · doi:10.1016/j.cell.2009.10.006 · Cited by 1,488
the Arizona Parkinson’s Disease Consortium, Beach, T. G., Adler, C. H., Lue, L., Sue, L. I., Bachalakuri, J., Henry-Watson, J., Sasse, J., Boyer, S., Shirohi, S., et al. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0538-8 · Cited by 698
Self-citationArizona Study of Aging and Neurodegenerative Disorders and Brain and Body Donation Program
Beach, T. G., Adler, C. H., Sue, L. I., Serrano, G., Shill, H. A., Walker, D. G., Lue, L., Roher, A. E., Dugger, B. N., Maarouf, C., et al. (2015) · Neuropathology · doi:10.1111/neup.12189 · Cited by 460 · cited 2×
“Human postmortem brain tissue sections that were fully characterized clinically and neuropathologically were obtained from the Banner Sun Health Research Institute Brain and Body Donation Program of Sun City, Arizona.(20) Deidentified samples from eight subjects in each”
MethodSelf-citationGong, C.-X., Lidsky, T., Wegiel, J., Zuck, L., Grundke-Iqbal, I., & Iqbal, K. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.8.5535 · Cited by 405
All roads lead to PP 2A: exploiting the therapeutic potential of this phosphatase
Sangodkar, J., Farrington, C. C., McClinch, K., Galsky, M. D., Kastrinsky, D. B., & Narla, G. (2016) · The FEBS Journal · doi:10.1111/febs.13573 · Cited by 312
Protein phosphatase 2A dysfunction in Alzheimer’s disease
Sontag, J.-M., & Sontag, E. (2014) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2014.00016 · Cited by 304 · cited 1×
“The present findings point to parallels in the dysregulation of PP2A, and in particular its methylation state, between a-synucleinopathies and Alzheimer’s disease.(34) Decreased phosphatase activity toward abnormally phosphorylated tau had been recognized in AD brains.”
Backgroundvan Eersel, J., Ke, Y. D., Liu, X., Delerue, F., Kril, J. J., Götz, J., & Ittner, L. M. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1009038107 · Cited by 284
Cited by
Alpha-synuclein: Pathology, mitochondrial dysfunction and neuroinflammation in Parkinson’s disease
Rocha, E. M., De Miranda, B., & Sanders, L. H. (2018) · Neurobiology of Disease · doi:10.1016/j.nbd.2017.04.004 · Cited by 762
Tau Pathology in Parkinson's Disease
Zhang, X., Gao, F., Wang, D., Li, C., Fu, Y., He, W., & Zhang, J. (2018) · Frontiers in Neurology · doi:10.3389/fneur.2018.00809 · Cited by 195
“Reduced activity levels of PP2A in the brains of patients with PD and AD indirectly confirmed this inference (50, 51).”
BackgroundSelf-citationKatila, N., Bhurtel, S., Shadfar, S., Srivastav, S., Neupane, S., Ojha, U., Jeong, G.-S., & Choi, D.-Y. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.08.015 · Cited by 169
Vecchio, L. M., Sullivan, P., Dunn, A. R., Bermejo, M. K., Fu, R., Masoud, S. T., Gregersen, E., Urs, N. M., Nazari, R., Jensen, P. H., et al. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15432 · Cited by 56
“First, oxidation products are known to stabilize α- synuclein oligomers (Conway et al. 2001; Mor et al. 2017), which have a diminished ability to regulate TH activity (Hua et al. 2015; Lou et al. 2010; Park et al. 2016; Peng et al. 2005; Wu et al. 2011).”
BackgroundKang, J.-B., Park, D.-J., Son, H.-K., & Koh, P.-O. (2020) · Laboratory Animal Research · doi:10.1186/s42826-020-00064-y · Cited by 3
Metadata
- Authors
- Park, H., Lee, K., Park, E. S., Oh, S., Yan, R., Zhang, J., Beach, T. G., Adler, C. H., Voronkov, M., Braithwaite, S. P., Stock, J. B., & Mouradian, M. M.
- Venue
- Annals of Clinical and Translational Neurology
- Publisher
- Wiley
- Published
- 2016-09-07
- Volume
- 3
- Issue
- 10
- Pages
- 769-780
- ISSN
- 2328-9503 (ISSN-L)
- OpenAlex
- W2515738886
- Cited by
- 66
- References
- 16
- FWCI
- 4.08
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Dysregulation of protein phosphatase 2A in parkinson disease and dementia with lewy bodies. https://app.cochat.ai/papers/10.1002/acn3.337
- The paper
- Park, H., Lee, K., Park, E. S., Oh, S., Yan, R., Zhang, J., Beach, T. G., Adler, C. H., Voronkov, M., Braithwaite, S. P., Stock, J. B., & Mouradian, M. M. (2016). Dysregulation of protein phosphatase 2A in parkinson disease and dementia with lewy bodies. Annals of Clinical and Translational Neurology. https://doi.org/10.1002/acn3.337
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.